Zeraatkar, Dena
Pitre, Tyler
Phillips, Mark http://orcid.org/0000-0003-0923-261X
Steel, David H. http://orcid.org/0000-0001-8734-3089
Wykoff, Charles C.
Wong, Tien Yin http://orcid.org/0000-0002-8448-1264
Bhandari, Mohit
Chaudhary, Varun http://orcid.org/0000-0002-9988-4146
Sivaprasad, Sobha
Thabane, Lehana
Kaiser, Peter
Sarraf, David
Bakri, Sophie J.
Garg, Sunir J.
Singh, Rishi P.
Holz, Frank G.
Wong, Tien Y.
Guymer, Robyn H.
Sadda, SriniVas R.
,
Article History
Received: 18 December 2023
Revised: 11 January 2024
Accepted: 16 January 2024
First Online: 5 February 2024
COMPETING INTERESTS
: DHS: Consultant: Gyroscope, Roche, Alcon, BVI; Research Funding: Alcon, Bayer, DORC, Gyrsocope, Boehringer-Ingelheim. CCW: Consultant: Acuela, Adverum Biotechnologies, Inc, Aerpio, Alimera Sciences, Allegro Ophthalmics, LLC, Allergan, Apellis Pharmaceuticals, Bayer AG, Chengdu Kanghong Pharmaceuticals Group Co, Ltd, Clearside Biomedical, DORC (Dutch Ophthalmic Research Center), EyePoint Pharmaceuticals, Gentech/Roche, GyroscopeTx, IVERIC bio, Kodiak Sciences Inc, Novartis AG, ONL Therapeutics, Oxurion NV, PolyPhotonix, Recens Medical, Regeron Pharmaceuticals, Inc, REGENXBIO Inc, Santen Pharmaceutical Co, Ltd, and Takeda Pharmaceutical Company Limited; Research funds: Adverum Biotechnologies, Inc, Aerie Pharmaceuticals, Inc, Aerpio, Alimera Sciences, Allergan, Apellis Pharmaceuticals, Chengdu Kanghong Pharmaceutical Group Co, Ltd, Clearside Biomedical, Gemini Therapeutics, Genentech/Roche, Graybug Vision, Inc, GyroscopeTx, Ionis Pharmaceuticals, IVERIC bio, Kodiak Sciences Inc, Neurotech LLC, Novartis AG, Opthea, Outlook Therapeutics, Inc, Recens Medical, Regeneron Pharmaceuticals, Inc, REGENXBIO Inc, Samsung Pharm Co, Ltd, Santen Pharmaceutical Co, Ltd, and Xbrane Biopharma AB. TYW: Consultant: Aldropika Therapeutics, Bayer, Boehringer Ingelheim, Genentech, Iveric Bio, Novartis, Plano, Oxurion, Roche, Sanofi, and Shanghai Henlius; Research funding: National Key R&D Program, China (grant number 2022YFC2502800); Investor, patent holder, and cofounder of the start-up companies EyRiS and Visre. MB: Research funding: Pendopharm, Bioventus, Acumed. VC: Advisory Board Member: Alcon, Roche, Bayer, Novartis; Grants: Bayer, Novartis – unrelated to this study.
Free to read: This content has been made available to all.